Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 12, 1999

View Archived Issues

Micrologix initiates phase II safety studies of fast-track development candidate

Animal model shows Toleragen reduces production of antiphospholipid antibodies

Full enrollment reached in phase III trial of GMK cancer vaccine

MS-377 improves positive and negative symptoms of schizophrenia, without causing EPS

Cerus awarded NIH grant for allogeneic bone marrow transplant research

RPR sublicenses hormone replacement products to Novartis

Experimental hepatitis B vaccine includes a novel adjuvant; efficacy in nonresponders

Enzo Biochem's HGTV43 achieves high levels of gene delivery to human cells

Titan receives NIH grant for support of Parkinson's disease therapy

Sheffield and Elan establish licensing agreement to develop respiratory products

Venlafaxine as a nonhormonal treatment for hot flashes associated with androgen deprivation

Licensing opportunity from NIH: novel integrin antagonists for treating inflammatory disease

NO-generating prodrugs available for licensing from NIH

EM-800 unexpectedly found to resemble raloxifene more closely than fulvestrant

FDA approves Prozac for treatment of geriatric depression

Gemin X discovers novel Bcl-2 inhibitor as anticancer agent

Several candidates in Fujisawa's pipeline progressing in phase II and III trials

New British Biotech esters inhibit tumor cell proliferation

Potent and selective alpha1-adrenoceptor ligands and their use presented by Lundbeck

Inhibitors of Src PTKs from BMS particularly useful for T-cell-mediated disorders

Selective beta3-adrenoceptor agonists in development at Merck

Decatromicins: novel antibiotics produced by Actinomadura

Initial results point to efficacy and safety of BCH-10652 in HIV-infected patients

Activity of new triazole antifungal BMS-207147 further characterized in vitro

Triangle presents promising data on Coactinon at ICAAC, but reports interaction with nelfinavir

Antiretroviral-naive patients respond similarly to lodenosine and lamivudine in combination regimens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...